Summary
Dihydropyrimidine dehydrogenase (DPD) is responsible for the breakdown of the widely used antineoplastic agent 5-fluorouracil (5FU), thereby limiting the efficacy of the therapy. To identify patients suffering from a complete or partial DPD deficiency, the activity of DPD is usually determined in peripheral blood mononuclear cells (PBM cells). In this study, we demonstrated that the highest activity of DPD was found in monocytes followed by that of lymphocytes, granulocytes and platelets, whereas no significant activity of DPD could be detected in erythrocytes. The activity of DPD in PBM cells proved to be intermediate compared with the DPD activity observed in monocytes and lymphocytes. The mean percentage of monocytes in the PBM cells obtained from cancer patients proved to be significantly higher than that observed in PBM cells obtained from healthy volunteers. Moreover, a profound positive correlation was observed between the DPD activity of PBM cells and the percentage of monocytes, thus introducing a large inter- and intrapatient variability in the activity of DPD and hindering the detection of patients with a partial DPD deficiency.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baker, S. D., Khor, S. P., Adjei, A. A., Doucette, M., Spector, T., Donehower, R. C., Grochow, L. B., Sartorius, S. E., Noe, D. A., Hohneker, J. A. & Rowinsky, E. K. (1996). Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14: 3085–3096.
Beuzeboc, P., Pierga, J-Y, Stoppa-Lyonnet, D., Etienne, M. C., Milano, G. & Pouillart, P. (1996). Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta. Eur J Cancer 32A: 370–371.
Born, J., Hansen, K., Mölle, M. & Fehm, H-L (1997). Effect of sleep and circadian rhythm on human circulating immune cells. J Immunol 158: 4454–4464.
Chazal, M., Etienne, M. C., Renée, N., Bourgeon, A., Richelme, H. & Milano, G. (1996). Link between dihydropyrimidine dehyrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res 2: 507–510.
Daher, G. C., Naguib, F. N. M., el Kouni, M. H., Zhang, R., Soong, S. J. & Diasio, R. B. (1991). Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil. Biochem Pharmacol 41: 1887–1893.
De Boer, M. & Roos, D. (1986). Metabolic comparison between basophils and other leukocytes from human blood. J Immunol 136: 3447–3454.
De Korte, D., Haverkort, W. A., Van Gennip, A. H. & Roos, D. (1985). Nucleotide profiles of normal blood cells determined by high-performance liquid chromatography. Anal Biochem 147: 197–209.
Diasio, R. B., Beavers, T. L. & Carpenter, J. T. (1988). Familial deficiency of dihydropyrimidine dehydrogenase, biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81: 47–51.
Diasio, R. B., Lu, Z., Zhang, R. & Shahinian, H. S. (1995). Fluoropyrimidine catabolism. Cancer Treatment Res 78: 71–93.
Etienne, M. C., Lagrange, J. L., Dassonville, O., Fleming, R., Thyss, A., Renée, N., Schneider, M., Demard, F. & Milano, G. (1994). Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12: 2248–2253.
Fernandez-Salguero, P., Gonzalez, F. J., Etienne, M. C., Milano, G. & Kimura, S. (1995). Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes. Biochem Pharmacol 50: 1015–1020.
Fleming, R. A., Milano, G., Thyss, A., Etienne, M-C, Renée, N., Schneider, M. & Demard, F. (1992). Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52: 2899–2902.
Fleming, R. A., Milano, G. A., Gaspard, M. H., Bargnoux, P. J., Thyss, A., Plagne, R., Reneé, M., Schneider, M. & Demard, F. (1993). Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 29A: 740–744.
Grem, J. L., Yee, L. K., Venzon, D. J., Takimoto, C. H. & Allegra, C. J. (1997). Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother Pharmacol 40: 117–125.
Harris, B. E., Song, R., Soong, S-J & Diasio, R. B. (1990). Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197–201.
Harris, B. E., Carpenter, J. T. & Diasio, R. B. (1991). Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. Cancer 68: 499–501.
Haus, E. (1992). Chronobiology of circulating blood cells and platelets. In Biologic Rhythms in Clinical and Laboratory Medicine, Touitou Y and Haus E (eds.), pp. 504–526, Springer Verlag: New York
Heggie, G. D., Sommadossi, J-P, Cross, D. S., Huster, W. J. & Diasio, R. B. (1987). Clinical pharmacokinetics of 5-fluorouracil and its metabolism in plasma, urine, and bile. Cancer Res 47: 2203–2206.
Ho, D. H., Townsend, L., Luna, M. A. & Bodey, G. P. (1986). Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 6: 781–784.
Houyau, P., Gay, C., Chatelut, E., Canal, P., Roché, H. & Milano, G. (1993). Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J Natl Cancer Inst 85: 1602–1603.
Kaffenberger, W., Hölzer-Müller, L., Auberger, T., Clasen, B. P. E., Hohlmeier, G. & Van Beuningen, D. (1995). An immunological outcome predictive score for head and neck carcinoma patients. Strahlenther Onkol 171: 444–453.
Lu, Z., Zhang, R. & Diasio, R. B. (1993). Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53: 5433–5438.
Lyss, A. P., Lilenbaum, R. C., Harris, B. E. & Diasio, R. B. (1993). Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest 11: 239–240.
Mackall, C. L., Fleisher, T. A., Brown, M. R., Magrath, I. T., Shad, A. T., Horowitz, M. E., Wexler, L. H., Adde, M. A., McClure, L. L. & Gress, R. E. (1994). Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 84: 2221–2228.
Maldonado, J. E. & Hanlon, D. G. (1965). Monocytosis: a current appraisal. Mayo Clin Proc 40: 248–259.
McMurrough, J. & McLeod, H. L. (1996). Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 41: 425–427.
Meinsma, R., Fernandez-Salguero, P., Van Kuilenburg, A. B. P., Van Gennip, A. H. & Gonzalez, F. J. (1995). Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uraciluria. DNA Cell Biol 14: 1–6.
Milano, G. & Etienne, M. C. (1994a). Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil. Anticancer Res 14: 2295–2298.
Milano, G. & Etienne, M. C. (1994b). Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics 4: 301–306.
Naguib, F. N. M., el Kouni, M. H. & Cha, S. (1985). Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405–5412.
Pero, R. W., Johnson, D. & Olsson, A. (1984). Catabolism of exogenously supplied thymidine to thymine and dihydrothymine by platelets in human peripheral blood. Cancer Res 44: 4955–4961.
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J. & Klenk, D. C. (1985). Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76–85.
Spector, T., Harrington, J. A. & Porter, D. J. T. (1993). 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46: 2243–2248.
Stéphan, F., Etienne, M. C., Wallays, C., Milano, G. & Clergue, F. (1995). Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am J Med 99: 685–688.
Strender, L. E., Blomgren, H., Petrini, B., Wasserman, J., Forsgren, M., Norberg, R., Baral, E. & Wallgren, A. (1981). Immunological monitoring in breast cancer patients receiving postoperative adjuvant chemotherapy. Cancer 48: 1996–2002.
Takamoto, C. H., Lu, Z-H, Zhang, R., Liang, M. D., Larson, L. V., Cantilena, L. R., Grem, J. L., Allegra, C. J., Diasio, R. B. & Chu, E. (1996). Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 2: 477–481.
Tuchman, M., Stoeckeler, J. S., Kiang, D. T., O’Dea, R. F., Ramnaraine, M. L. & Mirkin, B. L. (1985). Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313: 245–249.
Van Gennip, A. H., Busch, S., Elzinga, L., Stroomer, A. E. M., Van Cruchten, A., Scholten, E. G. & Abeling, NGGM (1993). Application of simple chromatographic methods for the diagnosis of defects in pyrimidine degradation. Clin Chem 39: 380–385.
Van Gennip, A. H., Abeling, NGGM, Stroomer, A. E. M., Van Lenthe, H. & Bakker, H. D. (1994). Clinical and biochemical findings in six patients with pyrimidine degradation defects. J Inherited Metab Dis 17: 130–132.
Van Gennip, A. H., Abeling, NGGM, Vreken, P. & Van Kuilenburg, A. B. P. (1997). Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. J Inherited Metab Dis 20: 203–213.
Van Kuilenburg, A. B. P., Van Lenthe, H. & Van Gennip, A. H. (1996). Identification and tissue-specific expression of a NADH-dependent activity of dihydropyrimidine dehydrogenase in man. Anticancer Res 16: 389–394.
Van Kuilenburg, A. B. P., Vreken, P., Beex, LVAM, Meinsma, R., Van Lenthe, H., De Abreu, R. A. & Van Gennip, A. H. (1997a). Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer 33: 2258–2264.
Van Kuilenburg, A. B. P., Van Lenthe, H., Wanders, R. J. A. & Van Gennip, A. H. (1997b). Subcellular localization of dihydropyrimidine dehydrogenase. Biol Chem 378: 1047–1053.
Van Kuilenburg, A. B. P., Vreken, P., Beex, LVAM, Meinsma, R., Van Lenthe, H., De Abreu, R. A. & Van Gennip, A. H. (1998a). Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Adv Exp Med Biol 431: 293–298.
Van Kuilenburg, A. B. P., Van Lenthe, H., Wanders, R. J. A. & Van Gennip, A. H. (1998b). Subcellular localization of dihydropyrimidine dehydrogenase. Adv Exp Med Biol 431: 817–821.
Van Kuilenburg, A. B. P., Poorter, R. L., Peters, G. J., Van Gennip, A. H., Van Lenthe, H., Stroomer, A. E. M., Smid, K., Noordhuis, P., Bakker, P. J. M. & Veenhof, C. H. N. (1998c). No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, β-alanine and 5-fluorouracil during continuous infusion of 5-fluorouracil. Adv Exp Med Biol 431: 811–816.
Vreken, P., Van Kuilenburg, A. B. P., Meinsma, R., Smit, G. P. A., Bakker, H. D., De Abreu, R. A. & Van Gennip, A. H. (1996). A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency. J Inherited Metab Dis 19: 645–654.
Vreken, P., Van Kuilenburg, A. B. P., Meinsma, R. & Van Gennip, A. H. (1997a). Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene. J Inherited Metab Dis 20: 335–338.
Vreken, P., Van Kuilenburg, A. B. P., Meinsma, R., De Abreu, R. A. & Van Gennip, A. H. (1997b). Identification of a four-base deletion (delTCAT296–299) in the dihydropyrimidine dehydrogenase gene with variable clinical expression. Hum Genet 100: 263–265.
Wei, X., McLeod, H. L., McMurrough, J., Gonzalez, F. J. & Fernandez-Salguero, P. (1996). Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 3: 610–615.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kuilenburg, A., Lenthe, H., Blom, M. et al. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer 79, 620–626 (1999). https://doi.org/10.1038/sj.bjc.6690097
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690097
Keywords
This article is cited by
-
Pharmacokinetic and toxicodynamic evaluation of 5-fluorouracil administration after major hepatectomy in a rat model
Cancer Chemotherapy and Pharmacology (2020)
-
The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study
British Journal of Cancer (2019)
-
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients
British Journal of Cancer (2017)
-
Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency
The Pharmacogenomics Journal (2013)
-
Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination
Analytical and Bioanalytical Chemistry (2013)